Breaking News, Collaborations & Alliances

WuXi Biologics, Aravive Ink Drug Development Deal

To develop novel high-affinity bispecific antibodies targeting cancer and fibrosis using the WuXiBody platform

By: Contract Pharma

Contract Pharma Staff

Clinical-stage biotech Aravive, and WuXi Biologics, have entered a collaboration granting Aravive the right to use the proprietary WuXiBody platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.   Aravive and WuXi Biologics will collaborate to discover antibodies against CCN2, a multidomain protein also known as connective tissue growth factor (CTGF). CCN2 was identified from a similar target discovery screen that identified the significance of th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters